Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study
18 Years - 130 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Sept 2023 by AstraZeneca
No locations available
Patients who have received Benralizumab.
Patients who have received non benralizumab biologics.
Patients who have received non biologic drug.